[back]

NovoCure Limited

Summary of Case:

Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, announces the commencement of an investigation into NovoCure Limited (NVCR) ("NovoCure").  If you are a NovoCure shareholder, you are encouraged to contact Scott+Scott at (800) 404-7770 or email mburnett@scott-scott.com to discuss your legal rights. 

NovoCure develops and commercializes treatment for solid tumor cancers therapy called the tumor treating fields ("TTFields"). NovoCure markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer.

On July 28, 2016, NovoCure announced that its new Optune prescriptions fell to 657 in 2Q from 755 in 1Q. Asaf Danziger, Chief Executive Officer of Novocure stated that "[w]hile barriers to full adoption remain, I am optimistic we will overcome the challenges inherent in bringing a completely new therapy into widespread clinical use."

On this news, NovoCure's stock fell from a July 27, 2016 price of $11.44 to a July 28, 2016 price of $8.09, a one-day decline of over 29%.

What You Can Do

If you are a NovoCure shareholder and you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Michael Burnett at (800) 404-7770, or at mburnett@scott-scott.com.

About Scott+Scott, Attorneys at Law, LLP

Scott+Scott have significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States.  The firm represents pension funds, foundations, individuals, and other entities worldwide.

CONTACT:

Michael Burnett

Scott+Scott, Attorneys at Law, LLP

(800) 404-7770

mburnett@scott-scott.com

If you purchased this company's shares during the Class Period and suffered a loss or for further information about the case, please review the links below.

[back]